https://www.cochrane.org/fr/CD009806/CF_lenzymotherapie-de-substitution-par-galsulfase-dans-la-mucopolysaccharidose-de-type-vi 2021 false false false false France United Kingdom French review of literature french abstract enzyme therapy mucopolysaccharidosis VI galsulfase mucopolysaccharidosis, nos Mucopolysaccharidosis
--- http://www.has-sante.fr/portail/jcms/c_1769786/fr/naglazyme-galsulfase-enzyme http://www.has-sante.fr/portail/jcms/c_1769786/fr/naglazyme http://www.has-sante.fr/portail/display.jsp?id=c_460176 2014 false France French guidelines for drug use galsulfase treatment outcome N-Acetylgalactosamine-4-Sulfatase recombinant proteins galsulfase galsulfase N-Acetylgalactosamine-4-Sulfatase enzyme replacement therapy recombinant proteins mucopolysaccharidosis VI infusions, intravenous orphan drug production evaluation of the transparency committee
--- http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=66966299 2012 France summary of product characteristics package leaflet galsulfase
--- https://www.ema.europa.eu/medicines/human/EPAR/Naglazyme 2012 United Kingdom French English syndication feed mucopolysaccharidosis VI N-Acetylgalactosamine-4-Sulfatase N-Acetylgalactosamine-4-Sulfatase N-Acetylgalactosamine-4-Sulfatase treatment outcome drug evaluation recombinant proteins recombinant proteins recombinant proteins infusions, intravenous orphan drug production pregnancy breast feeding N-Acetylgalactosamine-4-Sulfatase N-Acetylgalactosamine-4-Sulfatase recombinant proteins recombinant proteins drug evaluation, preclinical drug storage drug compounding drug approval drug labeling galsulfase galsulfase drug evaluation summary of product characteristics package leaflet